Abstract
Detection of BCR-ABL transcripts in chronic myeloid leukaemia (CML) is used to confirm the diagnosis and to monitor residual disease. Quantitative techniques are required to predict response to therapy or early relapse. We have evaluated an assay in which transcription-mediated amplification (TMA) of BCR-ABL and ABLtranscripts is achieved using reverse transcriptase and RNA polymerase. The products are quantified in the hybridisation protection assay (HPA) using acridinium ester-labelled DNA probes and chemiluminescence. The method is a single tube procedure which uses small amounts of RNA (<500 ng/triplicate analysis), is technically simple (requiring just two waterbaths and a luminometer), rapid (total assay time <4 h) and sensitive (capable of detecting one BCR-ABL-positive K562 cell in the presence of 104–105 BCR-ABL-negative cells). BCR-ABL signals from patient RNA samples were quantified relative to known amounts of K562 RNA and normalised to levels of ABL. BCR-ABL/ABL ratios ranged from 0.15 to 1.59 (median 0.65) in RNA from diagnostic blood or bone marrow of 18 CML patients and were ⩽0.0001 in 20 normal controls. Sequential samples analysed from six CML patients post-allogeneic bone marrow transplantation who relapsed and received donor lymphocyte infusions showed BCR-ABL/ABL ratios which reflected patient status or treatment. A BCR-ABL/ABL ratio of 0.01 served as a useful arbitrary indicator value, with results above and below this value generally correlating with relapse or remission, respectively.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM . The biology of chronic myeloid leukemia N Engl J Med 1999 341: 164–172
Sawyers CL . Chronic myeloid leukemia N Engl J Med 1999 340: 1330–1340
Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E, Hoffmann RG, Jacobsen SJ, Marmont AM, McGlave PB, Messner HA, Rimm AA, Rozman C, Speck B, Tura S, Weiner RS, Bortin MM . Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion Ann Intern Med 1988 108: 806–814
Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, Boulad F, Castro-Malaspina H, Childs BH, Gillio AP, Kernan NA . Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease Blood 1995 86: 1261–1268
Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL . Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 2001 344: 1031–1037
Druker BJ, Sawyers CL, Kantajian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M . Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome N Engl J Med 2001 344: 1038–1042
Yee K, Anglin P, Keating A . Molecular approaches to the detection and monitoring of chronic myeloid leukemia: theory and practice Blood Rev 1999 13: 105–126
Faderl S, Talpaz M, Kantarjian HM, Estrov Z . Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making? Blood 1999 93: 2755–2759
Thompson JD, Brodsky I, Yunis JJ . Molecular quantification of residual disease in chronic myelogenous leukemia after bone marrow transplantation Blood 1992 79: 1629–1635
Cross NC, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM . Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation Blood 1993 82: 1929–1936
Lion T, Henn T, Gaiger A, Kalhs P, Gadner H . Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukaemia Lancet 1993 341: 275–276
van Rhee F, Lin F, Cullis JO, Spencer A, Cross NC, Chase A, Garicochea B, Bungey J, Barrett J, Goldman JM . Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse Blood 1994 83: 3377–3383
Lin F, van Rhee F, Goldman JM, Cross NC . Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation Blood 1996 87: 4473–4478
Raanani P, Dazzi F, Sohal J, Szydlo RM, van Rhee F, Reiter A, Lin F, Goldman JM, Cross NC . The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation Br J Haematol 1997 99: 945–950
Mensink E, van de Locht A, Schattenberg A, Linders E, Schaap N, Geurts van Kessel A, De Witte T . Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR Br J Haematol 1998 102: 768–774
Preudhomme C, Revillion F, Merlat A, Hornez L, Roumier C, Duflos-Grardel N, Jouet JP, Cosson A, Peyrat JP, Fenaux P . Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a ‘real time’ quantitative RT-PCR assay Leukemia 1999 13: 957–964
Eder M, Battmer K, Kafert S, Stucki A, Ganser A, Hertenstein B . Monitoring of BCR-ABL expression using real-time RT-PCR in CML after bone marrow or peripheral blood stem cell transplantation Leukemia 1999 13: 1383–1389
Arnold LJ Jr, Hammond PW, Wiese WA, Nelson NC . Assay formats involving acridinium-ester-labeled DNA probes Clin Chem 1989 35: 1588–1594
Nelson NC . Rapid detection of genetic mutations using the chemiluminescent hybridization protection assay (HPA): overview and comparison with other methods Crit Rev Clin Lab Sci 1998 35: 369–414
Wu SQ, Voelkerding KV, Sabatini L, Chen XR, Huang J, Meisner LF . Extensive amplification of bcr/abl fusion genes clustered on three marker chromosomes in human leukemic cell line K-562 Leukemia 1995 9: 858–862
Hernandez A, Osterholz J, Price CM, Wiedemann LM, Gordon MY, Goldman JM, Morgan GJ . Detection of the hybrid BCR/ABL messenger RNA in single CFU-GM colonies using the polymerase chain reaction Exp Hematol 1990 18: 1142–1144
Compton J . Nucleic acid sequence-based amplification Nature 1991 350: 91–92
Sooknanan R, Malek L, Wang XH, Siebert T, Keating A . Detection and direct sequence identification of BCR-ABL mRNA in Ph+ chronic myeloid leukemia Exp Hematol 1993 21: 1719–1724
Dhingra K, Talpaz M, Riggs MG, Eastman PS, Zipf T, Ku S, Kurzrock R . Hybridization protection assay: a rapid, sensitive, and specific method for detection of Philadelphia chromosome-positive leukemias Blood 1991 77: 238–242
Melo JV . BCR-ABL gene variants Baillières Clin Haematol 1997 10: 203–222
Acknowledgements
The authors are grateful to Bill Hanna for critical review of the manuscript. This work was supported by the Kay Kendall Leukaemia Fund.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Langabeer, S., Gale, R., Harvey, R. et al. Transcription-mediated amplification and hybridisation protection assay to determine BCR-ABL transcript levels in patients with chronic myeloid leukaemia. Leukemia 16, 393–399 (2002). https://doi.org/10.1038/sj.leu.2402392
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2402392
Keywords
This article is cited by
-
Stopping tyrosine kinase inhibitors started after allogeneic HCT in patients with Philadelphia chromosome-positive leukemia
Bone Marrow Transplantation (2021)
-
Digital camera and smartphone as detectors in paper-based chemiluminometric genotyping of single nucleotide polymorphisms
Analytical and Bioanalytical Chemistry (2016)
-
A new diagnostic kit, ODK-1201, for the quantitation of low major BCR-ABL mRNA level in chronic myeloid leukemia: correlation of quantitation with major BCR-ABL mRNA kits
International Journal of Hematology (2015)
-
Myeloid blast crisis in chronic myeloid leukemia with a unique deletion near the BCR/ABL breakpoint
International Cancer Conference Journal (2015)
-
The European Treatment and Outcome Study score is associated with clinical outcomes and treatment response following European LeukemiaNet 2013 recommendations in chronic-phase chronic myeloid leukemia
International Journal of Hematology (2014)